Every 8-K that Novanta Inc. Tangible Equity Units (NOVTU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NOVTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NOVTU filings page.
Novanta Inc. reported strong results for the three months ended July 3, 2026, with GAAP revenue of $265.8 million, up 10.3% year-over-year and 9.3% organically. GAAP net income was $12.5 million and diluted EPS was $0.30, compared with $4.5 million and $0.12 a year earlier.
Non-GAAP performance also improved, with Adjusted Operating Income of $47.5 million, Adjusted EBITDA of $60.7 million (a 16.4% increase and 22.8% margin), and Adjusted Diluted EPS of $0.89, up 17.1% from $0.76. Operating cash flow rose to $64.9 million from $15.1 million, and year‑to‑date operating cash flow reached $116.5 million.
Novanta recently closed the acquisition of Riverpoint Medical, which it expects to be immediately accretive to revenue growth, gross margins, EBITDA margins, and EPS, roughly doubling recurring medical consumables to about 25% of sales and increasing medical end‑market exposure to about 60% of revenue. For full year 2026, the company guides to GAAP revenue of $1,130–$1,140 million, Adjusted EBITDA of $273–$278 million, and Adjusted Diluted EPS of $3.68–$3.74.
Novanta Inc. completed the acquisition of Riverpoint Medical by purchasing all equity of Runway Buyer on July 23, 2026. Buyer parties paid approximately $1.2 billion in cash at closing, plus a potential $250.0 million milestone payment due on or before January 8, 2027.
To fund the deal, an indirect subsidiary borrowed $616.0 million under its revolving and delayed draw term loan facilities, with the remainder from cash on hand, bringing consolidated debt to $854.7 million. The credit facilities mature in June 2030 and may be repaid early without penalty. Novanta states the acquisition is expected to roughly double recurring medical consumables revenue to $300 million, increase medical end-market exposure to 60% of total revenue, be immediately accretive to organic growth, margins, adjusted EBITDA and cash flows, and add $0.18–$0.25 of adjusted EPS in 2027.
Novanta Inc. entered into a Securities Purchase Agreement for a private placement of common shares expected to raise gross proceeds of approximately $300 million. Institutional and other accredited investors agreed to buy 2,142,857 common shares at $140.00 per share, with closing targeted for June 11, 2026, subject to customary conditions.
The shares are being sold in an unregistered transaction under Section 4(a)(2) of the Securities Act, and Novanta agreed in a Registration Rights Agreement to register their resale after closing. As of June 8, 2026, Novanta had 35,613,303 common shares outstanding; including a minimum 4,717,185 shares issuable under Tangible Equity Units, there would be 42,473,345 common shares outstanding or issuable following the closing.
Novanta Inc. is making a major move into minimally invasive surgical consumables by agreeing to acquire Riverpoint Medical for an upfront cash payment of $1.2 billion, plus a $250 million milestone payment expected in early 2027.
Riverpoint generates about $150 million in revenue with >50% adjusted gross margins, ~40% adjusted EBITDA margins and a 12%–15% organic growth outlook, roughly twice Novanta’s current growth rate. Novanta expects the deal to double recurring medical consumables revenue to roughly $300 million and increase medical end-market exposure to about 60% of total sales.
The transaction is expected to be immediately accretive to Novanta’s Adjusted Diluted EPS in 2026, and in 2027 accretive to revenue growth, adjusted margins, earnings and operating cash flow. It will be funded with cash on hand, existing credit facilities and a completed $300 million equity raise, with a targeted net leverage ratio of about 2.7x at closing and below 2.3x by year-end 2027.
Novanta Inc. reported the results of its 2026 annual meeting of shareholders. A total of 33,371,777 common shares were represented, equal to 93.71% of outstanding shares as of April 14, 2026. All nine director nominees received strong majority support and were elected for terms ending at the 2027 annual meeting.
Shareholders also approved, on an advisory basis, the Company’s executive compensation and ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm through the next annual meeting.
Novanta Inc. amended its main credit agreement to add $200.0 million in delayed draw term loan commitments. This new facility can be drawn at the company’s option for up to six months after May 15, 2026, giving additional funding flexibility.
The Delayed Draw Term Loans will mature on June 27, 2030 and bear interest at either the Base Rate plus 0.00%-0.75% or SOFR/SONIA/EURIBOR plus 1.00%-1.75%, depending on Novanta’s consolidated leverage ratio. The loans amortize quarterly starting with the fiscal quarter ending September 25, 2026, initially at 0.625% of outstanding U.S. dollar term loans, increasing to at least 1.25% from late June 2027. Novanta will also pay a commitment fee on undrawn amounts, and its incremental term loan and revolver capacity are reset from the amendment date.
Novanta Inc. reported solid first quarter 2026 results with growth in sales, earnings on a non-GAAP basis, and strong cash generation. GAAP revenue rose 10.4% to $257.7 million, helped by acquisitions and favorable currency, while organic revenue increased 3.1%. GAAP net income was stable at $21.1 million, but diluted EPS declined to $0.51 from $0.59 as operating expenses grew.
Profitability looked stronger on a non-GAAP basis. Adjusted EBITDA increased 14.2% to $57.1 million, with margin at 22.1%, and Adjusted diluted EPS rose to $0.81 from $0.74. Operating cash flow jumped to $51.6 million, driving Free Cash Flow of $47.8 million and leaving the company in a net cash position of about $139 million. Management highlighted 37% year-over-year bookings growth and guided Q2 2026 GAAP revenue to $259–$264 million, with full-year 2026 revenue expected between $1.04 billion and $1.055 billion, and higher Adjusted EBITDA and EPS, reflecting confidence in demand across medical and advanced industrial end markets.
Novanta Inc. reported steady growth for the fourth quarter and full year 2025 while laying out an ambitious 2026 outlook. Fourth quarter 2025 revenue reached $258.3 million, up 8.5% year over year, with GAAP diluted EPS of $0.45 versus $0.46 and Adjusted diluted EPS rising 20% to $0.91. Adjusted EBITDA grew 17% to $60.7 million, supported by a 25% increase in customer bookings and a book-to-bill of 1.11x.
For full year 2025, revenue was $980.6 million, up 3.3%. GAAP diluted EPS declined to $1.47 from $1.77, but Adjusted diluted EPS improved 6.8% to $3.29 and Adjusted EBITDA increased to $221.0 million. Operating cash flow fell to $64.1 million from $158.5 million, mainly due to higher working capital from regionalizing manufacturing.
Novanta ended 2025 with $380.9 million of cash and $250.8 million of total debt, resulting in Net Debt of $(121.3) million. For 2026, the company guides GAAP revenue to $1,030–$1,050 million, Adjusted EBITDA to $245–$250 million and Adjusted diluted EPS to $3.50–$3.65, with operating cash flow of $145–$185 million, and expects mid‑single‑digit organic growth.